Arcus Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary

Arcus Biosciences

05/08/2026 22:37

Arcus Biosciences, Inc. RCUS.N reported a quarterly adjusted loss of 72 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported breakeven earnings per share.  The mean expectation of twelve analysts for the quarter was for a loss of 90 cents per share. Wall Street expected results to range from $-1.04 to -68 cents per share.
Revenue fell 74.4% to $41.00 million from a year ago; analysts expected $23.41 million. 
Arcus Biosciences, Inc.'s reported EPS for the quarter was a loss of 72 cents​.
The company reported a quarterly loss of $91 million.
Arcus Biosciences, Inc. shares had fallen by 6.6% this quarter and gained 20.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 4.8% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Arcus Biosciences, Inc. is $38.00, about 24.2% above its last closing price of $28.80
This summary was machine generated from LSEG data August 5 at 09:37 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.90
-0.72
Beat
Mar. 31 2026 
-0.88
-1.02
Missed
Dec. 31 2025 
-1.03
-0.89
Beat
Sep. 30 2025 
-1.31
-1.27
Beat